

Kiribati

Support for Vaccine: Inactivated Polio Virus This Decision Letter sets out the Programme Terms of a Programme.

1.	Country:	Kiribati								
2.	Vaccine grai	nt number:	15-KIR-08h-Y, 1518-KIR-25d-X, 19-KIR-25d-X, 20-KIR-25d-X							
3.	Date of Deci	sion Letter:	30 September 2019							
4.	Date of the Partnership Framework Agreement (PFA): 22/07/2014									
5.	Programme title: New Vaccine Support (NVS), Inactivated Polio Virus, Routine									
6.	Vaccine type:		Inactivated Polio Virus							
7.	Requested product presentation and formulation of vaccine: Inactivated Polio Vaccine, 1 dose(s) per vial, LIQUID									
8.	Programme Duration: ¹ 2015-2020									
9.	Programme	Budget (indic	(subject to the terms of the PFA, if applicable)							
			2015	-2019	20	20	Total	2		
	Programme	Budget (US\$)		48,227	11,000			59,227		
10.	Vaccine introduction grant									
			Approval							
	Year		Grant Number		Amount (US\$)					
		2015	15-KIR	R-08h-Y		100,000				
	Disbursement									
		Disburser	ment date Amount (US\$)							
		21 Augu	st, 2014							
11.	Product swit	tch grant	Not applicabl	le						
12.	12. Indicative Annual Amounts: ³ (subject to the terms of the PFA, if applicable)									
	Type of su	pplies to be								

Type of supplies to be purchased with Gavi funds	2015-2019	2020	2021
Number of vaccine doses		3,700	-
Annual Amounts (US\$)	48,227	11,000	-

UNICEF. The Country shall release its co-financing payments each year to 13. Procurement agency: UNICEF.

14. Self-procurement: Not applicable - Procurement via Vaccine Indepenence Initiative (VII)

15. Co-financing obligations: Not applicable

Gavi's usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.



16. Operational support for campaigns: Not applicable

17. Additional Reporting Requirements:

		Due dates
	for the annual procurement of vaccines, Country shall submit the ormation each year:	
•	Vaccine stock levels including buffer stock, by end of March;	31 March 2020
•	Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May.	15 May 2020
•	Countries shall report the actual switch date in the first renewal request following the actual implementation.	
	ce with applicable Gavi processes, Country shall report on tic and financial performance.	To be agreed with Gavi Secretariat

18. Financial clarifications: Not applicable

19. Other conditions:

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

Signed by,

On behalf of Gavi

Thabani Maphosa

Managing Director, Country Programmes

30 September 2019